|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of ALCAM expression in relation to other molecular biomarkers revealed that ALCAM expression and the ALCAM/MMP-2 ratio are more promising indicators of breast cancer progression than MMP-2, E-cadherin, and alpha-catenin.
|
16810131 |
2006 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we studied DNA methylation status of the <i>ALCAM</i> gene using pyrosequencing in breast cancer tissues.
|
29315254 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our IHC results on primary breast carcinomas showed that ALCAM expression was associated with an estrogen receptor-positive phenotype.
|
20972617 |
2011 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gold nanoprobe-based method for sensing activated leukocyte cell adhesion molecule (ALCAM) gene expression, as a breast cancer biomarker.
|
26923994 |
2017 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The ALCAM transcript levels were lowest in patients with skeletal metastasis (p=0.0048) but were also significantly lower in patients who developed local recurrence (p=0.040) and in those who died from breast cancer (p=0.0075).
|
18202807 |
2008 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Little is known about the role of ALCAM levels in the serum of breast cancer patients.
|
22555284 |
2012 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival.
|
21935604 |
2012 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We tested the hypothesis that ALCAM expression would be markedly lower in cases of AA breast cancer when compared to CAU.
|
25255861 |
2014 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these data demonstrate that ALCAM is generally expressed in normal and cancerous breast epithelium and that a marked reduction of ALCAM expression characterizes a subset of breast cancer patients with adverse tumor characteristics and unfavorable clinical outcome.
|
25270339 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This report is the first evaluation of ALCAM/CD166 in an estrogen-dependent (MCF-7) and a metastatic (MDA-MB-231) breast cancer cell line and a reference breast cell line (HBL-100).
|
16865058 |
2006 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, ALCAM-silenced breast cancer cells exhibited reduced binding to Gal-8 relative to control cells.
|
27130882 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study investigated the biological influence of ALCAM on breast cancer cells in connection with bone biological environment.
|
20530423 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD166/ALCAM has gained increasing attention because of its significant association with tumor progression and the metastatic spread of breast cancer.
|
21293922 |
2011 |
|
Colorectal Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
We found that HOXA4 and HOXA9 are up-regulated in CRC SCs. siRNA knockdown of HOXA4 and HOXA9 reduced: (i) proliferation and sphere-formation and (ii) gene expression of known SC markers (ALDH1, CD166, LGR5).
|
28464221 |
2018 |
|
Colorectal Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Results showed that the difference in percentage of <i>KRAS</i> exon 2 mutations between CD166 positive and CD166 negative CRC specimens was significant (<i>P</i> < 0.05, chi-square test).
|
29755662 |
2018 |
|
Colorectal Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Importantly, analysis of patients with stage II CRC showed that disease-specific survival is significantly reduced for patients with elevated ALCAM shedding (P = 0.01; HR, 3.0), suggesting that ALCAM shedding can identify patients with early-stage disease at risk of rapid progression.
|
23539446 |
2013 |
|
Colorectal Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that CD166 expression may be correlated with CRC carcinogenesis and a decreased risk of vascular invasion, and it may become a predictive biomarker of survival for stage II CRC patients, but additional studies with large sample sizes are essential to validate the prognostic and predictive values of CD166 expression.
|
28969077 |
2017 |
|
Colorectal Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
These findings indicate that high ALCAM expression is associated with poor prognosis and advanced clinicopathological characteristics in CRC patients.
|
28537909 |
2017 |
|
Colorectal Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Analysis of the surface molecule repertoire of EpCAM(high)/CD44+ cells led to the identification of CD166 as an additional differentially expressed marker, useful for CSC isolation in three of three CRC tested.
|
17548814 |
2007 |
|
Colorectal Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Immunostaining showed that HOXA4 and HOXD10 are co-expressed with the SC markers CD166 and ALDH1 in cells at the normal crypt bottom, and the number of these co-expressing cells is increased in CRCs.
|
23980595 |
2014 |
|
Colorectal Carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that an increase in CSCs, specifically the CD44(+) CD166(-) phenotype in the colon could be a predisposing factor for the increased incidence of CRC among AAs.
|
26990997 |
2016 |
|
melanoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Here, we link miR-214 and ALCAM as well as identify a core role for miR-214 in organizing melanoma metastasis. miR-214 upregulated ALCAM, acting transcriptionally through TFAP2 and also posttranscriptionally through miR-148b (itself controlled by TFAP2), both negative regulators of ALCAM.
|
23667173 |
2013 |
|
melanoma
|
0.080 |
GeneticVariation
|
disease |
LHGDN |
Over the past decade, alterations in expression of ALCAM have been reported in several human tumors (melanoma, prostate cancer, breast cancer, colorectal carcinoma, bladder cancer, and esophageal squamous cell carcinoma).
|
18279810 |
2008 |
|
melanoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
One paraffin-embedded section of the patients' primary melanoma (n = 60), relapse (n = 21), and naevus (n = 17) were immunohistochemically double-stained for Ki-67/MART1 and single-stained for CD271, CD166, and CD20.
|
29678478 |
2018 |
|
melanoma
|
0.080 |
Biomarker
|
disease |
LHGDN |
These data indicate that the intact cell adhesion function of ALCAM may both favor primary tumor growth and represent a rate-limiting step for tissue invasion from VGP melanoma.
|
15140234 |
2004 |